Crispr Therapeutics AG (CRSP) Receives a Hold from Oppenheimer


Oppenheimer analyst Leah R. Cann maintained a Hold rating on Crispr Therapeutics AG (CRSP) today. The company’s shares opened today at $39.50.

Cann noted:

“Preclinical data for CTX120 presented at 2018 ASH were encouraging. CRISPR Therapeutics currently has one product in the clinic, CTX001. CTX110 and CTX120 are preclinical programs that could advance in the near term. With CTX120 showing activity both in vitro and in vivo xenograft re-challenge models and inhibiting tumor growth as late as 45 days after CAR-T administration, it appears to be a promising asset.”

According to TipRanks.com, Cann is a 4-star analyst with an average return of 6.9% and a 46.9% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $68.63 average price target.

See today’s analyst top recommended stocks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $50.71 million. In comparison, last year the company had a GAAP net loss of $24.71 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercializtion of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts